Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.
Thymidylate synthase (TYMS), the critical enzyme for DNA synthesis and a target for chemotherapy, was recently characterized as an oncogene and a potential target for specific immunotherapy. Here we report TYMS-specific antibody response in a fraction of colon cancer patients. Humoral immune response to TYMS is induced by chemotherapy using TYMS inhibitors, such as 5-fluorouracil (5-FU), and may be associated with tumor burden. Therefore, TYMS may serve as a useful serological biomarker for monitoring the course of disease and treatment in cancer patients.
Shebzukhov
Yuriy V
YV
Department of Molecular Immunology, Belozersky Institute of Physico-Chemical Biology, Moscow State University, Vorobjovy Gory, Moscow 119899, Russia.
Koroleva
Ekaterina P
EP
Khlgatian
Svetlana V
SV
Lagarkova
Maria A
MA
Meshcheryakov
Andrey A
AA
Lichinitser
Mikhail R
MR
Karbach
Julia
J
Jager
Elke
E
Kuprash
Dmitry V
DV
Nedospasov
Sergei A
SA
D000906:Antibodies / Q000097:blood* / Q000276:immunology; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D003110:Colonic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D013940:Thymidylate Synthase / Q000276:immunology*; D047368:Tumor Burden / Q000187:drug effects
D000906:Antibodies; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D013940:Thymidylate Synthase; D005472:Fluorouracil